8-K: BioMarin Reports Strong Q2 Growth, Raises Full-Year Guidance

BioMarin Pharmaceutical Inc. announced a 20% year-over-year increase in total revenue for the second quarter of 2024 and raised its full-year guidance.

Summary

• BioMarin's total revenue for the second quarter of 2024 reached $712 million, a 20% increase compared to the same period in 2023, or 25% at constant currency.
• First-half 2024 total revenue was $1.36 billion, up 14% year-over-year, or 19% at constant currency.
• GAAP diluted earnings per share (EPS) for Q2 2024 was $0.55, a 90% increase year-over-year, and $1.01 for the first half, an 80% increase year-over-year.
• Non-GAAP diluted EPS for Q2 2024 was $0.96, a 78% increase year-over-year, and $1.67 for the first half, a 46% increase year-over-year.
• VOXZOGO demand was strong, with a 73% year-over-year increase in the number of children receiving treatment, and nearly 900 new patient starts in the first half of 2024.
• Approximately 3,500 children were receiving VOXZOGO by the end of the second quarter.
• The company has updated its full-year 2024 guidance, projecting total revenues between $2.75 billion and $2.825 billion, a non-GAAP operating margin between 26% and 27%, and non-GAAP diluted EPS between $3.10 and $3.25.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong financial results, increased guidance, and positive clinical data. The company's strategic focus and pipeline progress also contribute to the high sentiment.

Positives

• Strong revenue growth driven by VOXZOGO and enzyme therapies.
• Significant increase in earnings per share (EPS) on both GAAP and non-GAAP basis.
• High demand for VOXZOGO, with a substantial increase in the number of children receiving treatment.
• Positive clinical data for VOXZOGO in multiple growth-related conditions.
• Increased full-year 2024 guidance for revenue, operating margin, and EPS.
• ROCTAVIAN is expected to be profitable by the end of 2025.
• The company has secured ample VOXZOGO supply to meet patient demand.
• The company is advancing its pipeline products, including BMN 351, BMN 349, and BMN 333.

Negatives

• KUVAN product revenues decreased due to generic competition.
• Increased spending in Selling, General and Administrative (SG&A) due to severance and restructuring costs.
• The company discontinued development of BMN 293, a gene therapy for hypertrophic cardiomyopathy.
• ROCTAVIAN expenses are being reduced to $60 million annually, indicating a change in strategy.

Risks

• The company faces risks related to the commercialization of its products.
• Macroeconomic and external factors could impact operations.
• Clinical trial results and regulatory decisions could affect product development.
• The company's ability to manufacture products successfully is a risk.
• Market acceptance of products is a risk.
• The company is subject to risks detailed in its filings with the Securities and Exchange Commission.

Future Outlook

BioMarin has raised its full-year 2024 guidance for total revenues to $2.75 billion to $2.825 billion, non-GAAP operating margin to 26% to 27%, and non-GAAP diluted EPS to $3.10 to $3.25. The company expects continued growth in VOXZOGO sales and anticipates ROCTAVIAN to be profitable by the end of 2025.

Management Comments

• Strong execution across our business resulted in record double-digit revenue growth in the second quarter and first half of 2024, said Alexander Hardy, President and Chief Executive Officer of BioMarin.
• Strong global demand for VOXZOGO led to nearly 900 new patient starts in the first half of 2024, the highest in VOXZOGOs history.
• We are seeing strong interest from families in the United States seeking VOXZOGO treatment for their children and we expect this market to continue to drive significant expansion over the coming quarters.
• With VOXZOGOs safety and efficacy well-established, based on nearly 6,000 patient years of demonstrated and durable evidence, we are confident in our rapidly expanding leadership.

Industry Context

BioMarin's strong performance reflects the growing demand for treatments for rare genetic disorders. The company's focus on innovative therapies and its success with VOXZOGO positions it well in the competitive biotechnology landscape. The strategic shift in ROCTAVIAN commercialization reflects the challenges of bringing gene therapies to market and the need for focused investment.

Comparison to Industry Standards

• BioMarin's 20% year-over-year revenue growth in Q2 2024 is strong compared to the average growth rate of many established biotech companies, which often see single-digit growth.
• The 78% year-over-year increase in non-GAAP diluted EPS is significantly higher than the industry average, indicating strong operational efficiency and profitability.
• Companies like Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN) are also known for strong revenue growth, but BioMarin's focus on rare diseases provides a unique market position.
• The strategic shift in ROCTAVIAN commercialization is similar to what other gene therapy companies like Bluebird Bio (BLUE) have experienced, highlighting the challenges of market access and reimbursement for these complex treatments.
• The company's focus on expanding VOXZOGO into new indications is a common strategy in the biotech industry to maximize the value of successful products, similar to how companies like Amgen (AMGN) expand the use of their blockbuster drugs.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, profitability, and positive outlook.
• Employees may be impacted by the restructuring efforts, but the company's overall growth is positive.
• Patients will benefit from the continued development and availability of innovative therapies.
• Customers will benefit from the company's commitment to meeting product demand.
• Suppliers will benefit from the company's continued growth and operations.
• Creditors will benefit from the company's improved financial position.

Next Steps

• BioMarin will hold an Investor Day on September 4th.
• The company will continue to enroll patients in clinical trials for VOXZOGO in hypochondroplasia, idiopathic short stature, Noonan Syndrome, Turner Syndrome and SHOX deficiency.
• BioMarin will begin enrolling its first-in-human study with BMN 349 later this year.
• The company plans to initiate a clinical program with BMN 333 in early 2025.

Key Dates

Keywords

BioMarin, VOXZOGO, ROCTAVIAN, revenue, EPS, achondroplasia, enzyme therapies, clinical trials, biotechnology, pharmaceutical